Haemofiltration - critical evaluation of clinical benefits.
To delineate the worth of chronic HF in end stage renal failure, since 1976 we have treated 9 patients with dialysis-resistant hypertension, 6 patients with dialysis intolerance, 7 patients with hypertriglyceridaemia and 7 patients with polyneuropathy. We found an improvement of polyneuropathy and volume-sodium dependent hypertension and symptoms of dialysis discomfort markedly diminished. No amelioration was detected in anaemia, hypertriglyceridaemia and volume-independent hypertension. Hyperphosphataemia was poorly controlled despite increased amounts of aluminium hydroxide. PTH values increased and renal osteopathy seemed to deteriorate.
D000138:Acidosis / Q000378:metabolism; D001769:Blood; D001803:Blood Transfusion; D005260:Female; D005293:Ferritins / Q000097:blood; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000150:complications; D007668:Kidney / Q000000981:diagnostic imaging; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D050356:Lipid Metabolism; D008297:Male; D011859:Radiography; D006435:Renal Dialysis; D014462:Ultrafiltration; D014511:Uremia / Q000628:therapy
D005293:Ferritins